azomycin has been researched along with Bone Cancer in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chezal, JM; Degoul, F; Jouberton, E; Maubert, E; Miot-Noirault, É; Peyrode, C; Voissiere, A | 1 |
| Atkins, GJ; DeNichilo, M; Difelice, C; Evdokiou, A; Findlay, DM; Hay, S; Ingman, W; Liapis, V; Panagopoulos, V; Ponomarev, V; Shoubridge, A; Zannettino, ACW; Zinonos, I; Zysk, A | 1 |
| Atkins, GJ; DeNichilo, M; Evdokiou, A; Findlay, DM; Hay, S; Ingman, W; Labrinidis, A; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, ACW; Zinonos, I | 1 |
| de Waal, EG; Kluin, PM; Leene, MJ; Slart, RH; Vellenga, E | 1 |
| Atkins, GJ; DeNichilo, M; Evdokiou, A; Findlay, DM; Hay, S; Ingman, W; Labrinidis, A; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, AC; Zinonos, I; Zysk, A | 1 |
| Brustad, T; Rofstad, EK | 1 |
| Abe, M; Hosotani, R; Imamura, M; Manabe, T; Nishimura, Y; Ohshio, G; Shibamoto, Y | 1 |
| Bataini, JP; Bernier, J; Brugère, J; Brunin, F; de Narbonne, J; Jaulerry, C | 1 |
2 trial(s) available for azomycin and Bone Cancer
| Article | Year |
|---|---|
A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Child; Combined Modality Therapy; Female; Humans; Intraoperative Care; Male; Middle Aged; Nitroimidazoles; Osteosarcoma; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 1997 |
[Clinical testing of the radiosensitizer RO-07-0582 (misonidazole). Dose tolerance, toxicity and pharmacokinetic studies, preliminary report (author's transl)].
Topics: Bone Neoplasms; Clinical Trials as Topic; Glioma; Humans; Kinetics; Misonidazole; Neoplasms; Nitroimidazoles; Otorhinolaryngologic Diseases; Sarcoma | 1978 |
6 other study(ies) available for azomycin and Bone Cancer
| Article | Year |
|---|---|
Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Nitroimidazoles; Phosphoramide Mustards; Spheroids, Cellular; Tissue Scaffolds | 2017 |
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Humans; Nitroimidazoles; Osteosarcoma; Phosphoramide Mustards; Prodrugs; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2017 |
Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Hypoxia; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Nitroimidazoles; Osteosarcoma; Phosphoramide Mustards; Prodrugs | 2015 |
18F-FDG PET increases visibility of bone lesions in relapsed multiple myeloma: is this hypoxia-driven?
Topics: Basic Helix-Loop-Helix Transcription Factors; Bone Marrow; Bone Neoplasms; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Multiple Myeloma; Nitroimidazoles; Positron-Emission Tomography; Radiopharmaceuticals; Vascular Endothelial Growth Factor A | 2015 |
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Nitroimidazoles; Paclitaxel; Phosphoramide Mustards; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Radiosensitizing effect of misonidazole in acute and fractionated irradiation of a human osteosarcoma xenograft.
Topics: Adolescent; Animals; Bone Neoplasms; Dose-Response Relationship, Radiation; Humans; Male; Mice; Mice, Nude; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Osteosarcoma; Transplantation, Heterologous | 1980 |